Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans
Authors:
Open Access
- 1 March 2015
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 1769-90
Abstract
In the present study, we developed a self-assembled biodegradable polyglutamic acid (PGA)-based formulation of amphotericin B (AmB) and evaluated its in vitro antifungal potential against Candida albicans. The AmB-loaded PGA nanoparticles were prepared in-house and had a mean size dimension of around 98±2 nm with a zeta potential of -35.2±7.3 mV. Spectroscopic studies revealed that the drug predominantly acquires an aggregated form inside the formulation with an aggregation ratio above 2. The PGA-based AmB formulation was shown to be highly stable in phosphate-buffered saline as well as in serum (only 10%–20% of the drug was released after 10 days). The AmB-PGA nanoparticles were less toxic to red blood cells (®, a commercial antifungal product. An MTT assay showed that the viability of mammalian cells (KB and RAW 264.7) was negligibly affected at AmB concentrations as high as 200 µg/mL. Histopathological examination of mouse kidney revealed no signs of tissue necrosis. The AmB-PGA formulation showed potent antimicrobial activity similar to that of Fungizone against C. albicans. Interestingly, AmB-bearing PGA nanoparticles were found to inhibit biofilm formation to a considerable extent. In summary, AmB-PGA nanoparticles showed highly attenuated toxicity when compared with Fungizone, while retaining equivalent active antifungal properties. This study indicates that the AmB-PGA preparation could be a promising treatment for various fungal infections.Keywords
This publication has 90 references indexed in Scilit:
- Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acidBiomaterials, 2011
- Encapsulation and Release of Amphotericin B from an ABC Triblock Fluorous CopolymerPharmaceutical Research, 2011
- Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin BInternational Journal of Pharmaceutics, 2011
- Enhanced Stability of PEG-block-poly(N-hexyl stearate l-aspartamide) Micelles in the Presence of Serum ProteinsMolecular Pharmaceutics, 2010
- N-(2-hydroxypropyl)methacrylamide–amphotericin B (HPMA–AmB) copolymer conjugates as antileishmanial agentsInternational Journal of Antimicrobial Agents, 2009
- Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancerBritish Journal of Cancer, 2008
- Polymer-drug conjugates: Recent development in clinical oncologyAdvanced Drug Delivery Reviews, 2008
- Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potentialBiomaterials, 2007
- A cost‐effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UKEuropean Journal of Haematology, 2007
- Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis ModelAntimicrobial Agents and Chemotherapy, 2006